Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 GDC-9545 ER+ HER2- BC (lidERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)
View
Description: GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
View
Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
View
Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
View
Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
View
Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
View
Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
View
Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)
Indication:
Breast Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
View
Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III
Title:
Ph3 AZD5305 vs Placebo in Men with Metastatic Castration-sensitive Prostate Cancer
View
Description: A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of Saruparib (AZD5305) in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) D9723C00001
Indication:
Prostate Cancer
Location:
Texas Oncology-Fredericksburg
Phase: III
Title:
Ph3 AZD5305 vs Placebo in Men with Metastatic Castration-sensitive Prostate Cancer
View
Description: A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of Saruparib (AZD5305) in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) D9723C00001
Indication:
Prostate Cancer
Location:
Texas Oncology-New Braunfels
Phase: III
Title:
Ph3 AZD5305 vs Placebo in Men with Metastatic Castration-sensitive Prostate Cancer
View
Description: A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of Saruparib (AZD5305) in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) D9723C00001
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Stone Oak
Phase: III
Title:
Ph3 AZD5305 vs Placebo in Men with Metastatic Castration-sensitive Prostate Cancer
View
Description: A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of Saruparib (AZD5305) in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) D9723C00001
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Northeast
Phase: III
Title:
Ph3 AZD5305 vs Placebo in Men with Metastatic Castration-sensitive Prostate Cancer
View
Description: A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of Saruparib (AZD5305) in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) D9723C00001
Indication:
Prostate Cancer
Location:
Texas Oncology-San Antonio Medical Center
Phase: III